Codexis Inc. (CDXS), an enzyme engineering company, is setting its sights on achieving profitability by the end of 2026, driven by the growing demand for its innovative enzymatic solutions.
The company uses its proprietary CodeEvolver directed evolution technology platform to develop optimized enzymes that are used by some of the world's largest pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It has collaborations and agreements with GSK, Merck, Novartis, Roche, Aldevron, Nestlé Health Science, Crosswalk Therapeutics and Alphazyme.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.